You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.
The company is seeing increasing interest in its GeoMx platform with numerous studies from early users presented last month at AACR.
The upgrades include a method to connect Panther systems to create a higher-throughput system that can be configured to different footprints.
Though the test is already commercially available, the firm met with the FDA last year to discuss plans for a randomized controlled trial to support regulatory approval.
The Maxpar Direct Immune Profiling System could lower the threshold to doing mass cytometry due to ease of use, a core lab director said.
The new IQvia E360 Genomics build includes a "privacy-preserving" database system and will soon have analytic tools to support genotype-phenotype research.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
Microba currently offers a direct-to-consumer gut microbiome profile product and plans to release additional products for clinical and research use cases.
The Polish company recently received 9 million Polish złoty ($2.4 million) from the country's National Center for Research and Development to support its activities.
The company has begun piloting the software, which is targeted towards bioinformatics companies and clinical laboratories, with early adopters ahead of the planned launch.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.